Autosomal recessive mutations in the development of Parkinsons disease

Biomarkers in Medicine

Volumn 4, Issue 5, 2010, Pages 713-721

  Lopez, Grisel ^a   Sidransky, Ellen ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

ATP13A2; DJ1; Gaucher disease; genetics; glucocerebrosidase; parkin; Parkinson's disease; PINK1; recessive; susceptibility

Indexed keywords

DJ 1 PROTEIN; GLUCOSYLCERAMIDASE; LEVODOPA; LIGASE; PARKIN; PROTEIN ATP13A2; PROTEIN PINK1; UNCLASSIFIED DRUG;

AUTOSOMAL RECESSIVE DISORDER; CLINICAL FEATURE; DRUG RESPONSE; DYSKINESIA; ENZYME ACTIVITY; GAUCHER DISEASE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HETEROZYGOSITY; HUMAN; LEWY BODY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PROTEIN FUNCTION; REVIEW; RISK FACTOR;

GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; ONCOGENE PROTEINS; PARKINSON DISEASE; PROTEIN KINASES; PROTON-TRANSLOCATING ATPASES; UBIQUITIN-PROTEIN LIGASES;

EID: 77958050398     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.96     Document Type: Review

References (67)

1. Willis AW, Evanoff BA, Lian M, Criswell SR, Racette BA: Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology 34, 143-151 (2010).
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinic-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55(3), 181-184 (1992).
3. Lesage S, Brice A: Parkinson's disease: from monogenic forms to genetic susceptibility factors Hum. Mol. Genet. 18(R1), R48-R59 (2009).
4. Sidransky E: Heterozygosity for a Mendelian disorder as a risk factor for complex disease. Clin. Genet. 70, 275-282 (2006).
5. Takahashi H, Ohama E, Suzuki S et al.: Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 44, 437-441 (1994).
6. Ohsawa Y, Kurokawa K, Sonoo M et al.: Reduced amplitude of the sural nerve sensory action potential in PARK2 patients. Neurology 65(3), 459-462 (2005).
7. Klein C, Schlossmacher MG: Parkinson disease, 10 years afer its genetic revolution: multiple clues to a complex disorder. Neurology 69(22), 2093-2104 (2007).
8. Pramstaller PP, Schlossmacher MG, Jacques TS et al.: Lewy body Parkinson's disease in a large pedigree with 77 parkin mutation carriers. Ann. Neurol. 58(3), 411-422 (2005).
9. Liu C, Choe V, Rao H: Genome-wide approaches to systematically indentify substrates of the ubiquitin-proteasome pathway. Trends Biotechnol. 28(9), 461-467 (2010).
10. Xiong H, Wang D, Chen L et al.: Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J. Clin. Invest. 119(3), 650-660 (2009).
11. Sriram SR, Li X, Ko HS et al.: Familial associated mutations differentially disrup the solubility, localization, binding and ubiquitination properties of parkin. Hum. Mol. Genet. 14(17), 2571-2586 (2005).
12. von Coelln R, Dawson VL, Dawson TM: Parkin-associated Parkinson's disease. Cell Tissue Res. 318(1), 175-184 (2004).
13. Goldberg MS, Fleming SM, Palacino JJ et al.: Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminegic neurons. J. Biol. Chem. 278(44), 43628-43635 (2003).
14. Palacino JJ, Sagi D, Goldberg MS et al.: Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279(18), 18614-18622 (2004).
15. Narendra DP, Jin SM, Tanaka A et al.: PINK1 is selectively stabilized on impaired mitochondria to activate parkin. PLoS Biol. 8(1), e1000298 (2010).
16. Poole AC, Thomas RE, Andrews LA, McBride HM, Whitworth AJ, Pallanck LJ: The PINK1/parkin pathway regulates mitochondrial morphology. Proc. Natl Acad. Sci. USA 105, 1638-1643 (2008).
17. Valente EM, Salvi S, Ialongo T et al.: PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann. Neurol. 56(3), 336-341 (2004).
18. Ephraty L, Porat O, Israeli D et al.: Neuropsychiatric and cognitive features in autosomal-recessive early parkinsonism due to PINK1 mutations. Mov. Disord. 22(4), 566-569 (2007).
19. Jendrach M, Gispert S, Ricciardi F, Klinkenberg M, Schemm R, Auburger G: The mitochondrial kinase PINK1, stress response and Parkinson's disease. J. Bioenerg. Biomembr. 41(6), 481-486 (2009).
20. Gispert S, Ricciardi F, Kurz A et al.: Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS ONE 4(6), e5777 (2009).
21. Chu CT: A pivotal role for PINK1 and autophagy in mitochondrial quality control: implications for Parkinson disease. Hum. Mol. Genet. 19(R1), R28-R37 (2010).
22. Weihofen A, Ostaszewski B, Minami Y, Selkoe DJ: PINK1 Parkinson mutations, the CDC37/Hsp90 chaperones and parkin all influence the maturation or subcellular distribution of PINK1. Hum. Mol. Genet. 17(4), 602-616 (2008).
23. Yang Y, Lu B: Mitochondrial morphogenesis, distribution, and Parkinson disease: insights from PINK1. J. Neuropathol. Exp. Neurol. 68(9), 953-963 (2009).
24. Bonifati V, Rizzu P, van Baren MJ et al.: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299(5604), 256-259 (2003). (Pubitemid 36131051)
25. Annesi G, Savettieri G, Pugliese P et al.: DJ-1 mutations and parkinsonism-dementia- amyotrophic lateral sclerosis complex. Ann. Neurol. 58, 803-807 (2005).
26. Dekker M, Bonifati V, van Swieten J et al.: Clinical features and neuroimaging of PARK7-linked parkinsonism. Mov. Disord. 18, 751-757 (2003).
27. Nagakubo D, Taira T, Kitaura H et al.: DJ-1 a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem. Biophys. Res. Commun. 231(2), 509-513 (1997).
28. Wagenfeld A, Yeung CH, Strupat K, Cooper TG: Shedding of a rat epididymal sperm proein associated with infertility induced by ornidazole and a-chlorohydrin. Biol. Reprod. 58(5), 1257-1265 (1998).
29. Zhou W, Freed C: DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T a-synuclein toxicity. J. Biol. Chem. 280, 43150-43158 (2005).
30. Canet-Avilés RM, Wilson MA, Miller DW et al.: The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl Acad. Sci. USA 101, 9103-9108 (2004).
31. Junn E, Taniguchi H, Jeong BS, Zhao X, Ichijo H, Mouradian MM: Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc. Natl Acad. Sci. USA 102(27), 9691-9696 (2005).
32. Liu F, Nguyen JL, Hulleman JD, Li L, Rochet JC: Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson's disease. J. Neurochem. 105, 2435-2453 (2008).
33. Manning-Bog AB, Caudle WM, Perez XA et al.: Increased vulnerability of nigrostriatal terminals in DJ-1 deficient mice is mediated by by the dopamine transporter. Neurobiol. Dis. 27, 141-150 (2007).
34. Aleyasin H, Rousseaux MW, Phillips M et al.: The Parkinson's disease gene DJ-1 is also a key regulator of stroke-induced damage. Proc. Natl Acad. Sci. USA 104, 18748-18753 (2007).
35. Al-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M: Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol. Scand. 89(5), 347-352 (1994).
36. Ramirez A, Heimbach A, Gründemann J et al.: Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38(10), 1184-1191 (2006).
37. Di Fonzo A, Chien HF, Socal M et al.; Italian Parkinson Genetics Network: ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 68(19), 1557-1562 (2007).
38. Williams DR, Hadeed A, al-Din AS, Wreikat AL, Lees AJ: Kufor-Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov. Disord. 20(10), 1264-1271 (2005).
39. Schneider SA, Paisan-Ruiz C, Quinn NP: ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov. Disord. 25(8), 979-984 (2010).
40. Lesage S, Brice A: Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18, R48-R59 (2009).
41. Gitler AD, Chesi A, Geddie ML et al.: a-Synuclein is part of a diverse and highly conserved interaction network that includes PARK 9 and manganese toxicity. Nat. Genet. 41(3), 308-315 (2009).
42. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE: Deciphering the role of heterozygous mutation in genes associated with parkinsonism. Lancet Neurol. 6, 652-662 (2007).
43. Khan NL, Scherfler C, Graham E et al.: Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 64, 134-136 (2005).
44. Pavese N, Khan NL, Scherfler C: Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-Dopa PET progression study. Mov. Disord. 24(15), 2260-2266 (2009).
45. Neudorfer O, Giladi N, Elstein D et al.: Occurence of Parkinson's syndrome in type 1 Gaucher disease. Q. J. Med. 89, 691-694 (1996). (Pubitemid 26319021)
46. Bembi B, Zambito Marsala S, Sidransky E et al.: Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 61(1), 99-101 (2003).
47. Tayebi N, Stubblefield BK, Park JK et al.: Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: implications for complexity in Gaucher disease. Am. J. Hum. Genet. 72(3), 519-534 (2003).
48. Orvisky E, Park JK, LaMarca ME et al.: Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol. Genet. Metab. 76(4), 262-270 (2002).
49. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E: Glucocerebrosidase mutations in subjects with parkinsonism. Mol. Genet. Metab. 81, 70-73 (2004).
50. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E: Parkinsonism among Gaucher disease carriers. J. Med. Genet. 41, 937-940 (2004).
51. Halperin A, Elstein D, Zimran A: Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol. Dis. 36(3), 426-428 (2006).
52. Saunders-Pullman R, Hagenah J, Dhawan V et al.: Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization. Mov. Disord. 25(10), 1364-1372 (2010).
53. Sidransky E, Nalls MA, Aasly JO et al.: Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361(17), 1651-1661 (2009).
54. Bultron G, Kacena K, Pearson D et al.: The risk of Parkinson's disease in type 1 Gaucher disease. J. Inherit. Metab. Dis. 33, 167-173 (2010).
55. Gan-Or Z, Giladi N, Rozovski U et al.: Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70, 2277-2283 (2008).
56. Neumann J, Bras J, Deas E et al.: Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132(Pt 7), 1783-1794 (2009).
57. Mitsui J, Mizuta I, Toyoda A et al.: Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch. Neurol. 66(5), 571-576 (2009).
58. Yang H, Zhou HY, Li B, Niu GZ, Chen SD: Downregulation of parkin damages antioxidant defenses and enhances proteasome inhibition-induced toxicity in PC12 cell. J. Neuroimmune. Pharmacol. 2, 276-283 (2007).
59. Yokota T, Sugawara K, Ito K, Takahashi R, Ariga H, Mizusawa H: Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem. Biophys. Res. Commun. 312, 1342-1348 (2003).
60. Seet RC, Lee CY, Lim EC et al.: Oxidative damage in Parkinson disease: measurement using accurate biomarkers. Free Radic. Biol. Med. 48(4), 560-566 (2010).
61. Singleton AB, Farrer M, Johnson J et al.: a-synuclein locus triplication causes Parkinson's disease. Science 302(5646), 841 (2003).
62. Xilouri M, Vogiatzi T, Vekrellis K et al.: Abberant a-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS ONE 4(5), e5515 (2009).
63. Chiba-Falek O, Nussbaum RL: Effect of allelic variation at the NACP-Rep1 repeat upstream of the a-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum. Mol. Genet. 10(26), 3101-3109 (2001).
64. Mizuta I, Satake W, Nakabayashi Y et al.: Multiple candidate gene analysis identifies a-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum. Mol. Genet. 15(7), 1151-1158 (2006).
65. Goris A, Williams-Gray CH, Clark GR et al.: Tau and a-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann. Neurol. 62(2), 145-153 (2007).
66. Farrer MJ, Stone JT, Lin CH et al.: Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat. Disord. 13(2), 89-92 (2007).
67. Velayati A, Yu WH, Sidransky E: The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr. Neurol. Neurosci. Rep. 10(3), 190-198 (2010).